Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals promising five-year results.
InvestorsHub on MSN
FDA clears Merck’s Keytruda and Keytruda QLEX for platinum-resistant ovarian cancer
The U.S. Food and Drug Administration has granted approval to Merck & Co. (NYSE:MRK) for the use of KEYTRUDA and KEYTRUDA QLEX, in combination with paclitaxel, with or without bevacizumab, to treat ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...
Sept 19 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved a new formulation of Merck's (MRK.N), opens new tab blockbuster cancer therapy Keytruda that can be ...
Merck MRK is focusing on driving its long-term growth with its new products and a promising set of pipeline candidates as its blockbuster PD-L1 inhibitor, Keytruda, faces patent expiration in 2028.
Feb 4 (Reuters) - Some cancer therapies may be more effective when given earlier in the day, aligning treatment with the body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results